The biopharmaceutical company Rhizen transferred their headquarters from La Chaux-de-Fonds in the canton of Neuenburg to Basel-Stadt in December 2020.

Founded in 2008 as a discovery and development company, Rhizen has developed into a leading oncology specialist. In 2021, Rhizen got accelerated approval for Umbralisib from the Food and Drug Administration in the U.S. The cancer treatment comes from a pipeline of internally discovered novel small molecule programs.

At the main location in Basel, Rhizen focuses on the clinical development and commercialization of novel oncology and inflammation medicines. Here, the company benefits from the proximity to the Basel Area life sciences cluster. It furthermore plans to grow and create local jobs.